We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 246

China’s New State Market Regulatory Administration: What to Know and What to Expect
  • Ropes & Gray LLP
  • China
  • April 3 2018

On March 17, China’s highest legislative body, the National People’s Congress, approved a sweeping government restructuring plan. This is generally


Overseas Clinical Trial Data of Medical Devices will be accepted by the CFDA, 10 January
  • CMS, China
  • China
  • March 27 2018

The CFDA announced the Technical Guidelines on the Acceptance of Data Derived from Overseas Clinical Trials of Medical Devices ("Guidelines") on the


The CFDA solicits public comments on infant formula food regulation, 30 January
  • CMS, China
  • China
  • March 27 2018

The CFDA published the Circular on Seeking Public Comments on the Administrative Measures for the Record-filing of Infant Formula Foods ("Draft"


New regulatory authorities for the Life Sciences and Healthcare sectors, 17 March
  • CMS, China
  • China
  • March 27 2018

The 13th National People's Congress passed the Programme of Reforming the Institutions of the State Council on the 17 March 2018. The CFDA will be


The CFDA further cracking down on food safety issues, 21 March
  • CMS, China
  • China
  • March 27 2018

The China Food and Drug Administration ("CFDA") announced that it will take serious measures to crack down on food safety issues, particularly on the


The CFDA solicits public comments to regulate Internet pharmacies, 9 February
  • CMS, China
  • China
  • March 27 2018

The CFDA announced the Circular on the Measures for the Supervision and Administration of Online Drug Sales ("Draft"). Under the Draft, manufacturers


China’s massive government restructure explained
  • Herbert Smith Freehills LLP
  • China
  • March 26 2018

China’s recently announced government restructure is the largest of its kind since China’s open door policy began in the late 1970s. The restructuring


China reorganises administrative authorities - new regulatory authorities for Life Sciences and Healthcare sector
  • CMS, China
  • China
  • March 20 2018

Recently, the 13th National People's Congress ("NPC") of the People's Republic of China passed the Programme of Reforming the Institutions of the


CFDA Continues to Expand Oversea Inspection
  • Hogan Lovells
  • China
  • March 12 2018

On Feb 27th, China Food and Drug Administration (CFDA) published their inspection reports for eight international medical device manufacturers located


Hong Kong Exchange Publishes Draft Rules for Biotech Listings, Requests Comments
  • Jones Day
  • Hong Kong
  • March 9 2018

The Stock Exchange of Hong Kong Limited (the "Exchange") published the Consultation Paper on a Listing Regime for Companies from Emerging and